,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant, based upon the last reported sale price of the common stock on the New York Stock Exchange on June 30, 2020, was $36.8 billion.",36.8,['Public Float'],dei_EntityPublicFloat,monetaryItemType,cnc,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant, based upon the last reported sale price of the common stock on the New York Stock Exchange on June 30, 2020, was $36.8 billion.",$36.8 billion,MONEY,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant, based upon the last reported sale price of the common stock on the New York Stock Exchange on June 30, 2020, was $36.8 billion.","['aggregate market value', 'non affiliates of registrant', 'last reported sale price of common stock', 'common stock on York Stock Exchange', 'last reported sale price on June', 'aggregate market value', 'common equity', 'non affiliates', 'last sale price', 'common stock']","['last reported sale price of common stock', 0.969526469707489, 'what is last reported sale price of common stock ?', '$36.8 billion']",last reported sale price of common stock,0.969526469707489,what is last reported sale price of common stock ?,$36.8 billion,Aggregate market value of voting and non voting common equity held by non affiliates
1,"As of February 19, 2021, the registrant had 581,593,037 shares of common stock issued and outstanding.","581,593,037","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,cnc,"As of February 19, 2021, the registrant had 581,593,037 shares of common stock issued and outstanding.","581,593,037",CARDINAL,"As of February 19, 2021, the registrant had 581,593,037 shares of common stock issued and outstanding.","['shares of common stock', 'common stock']","['shares of common stock', 0.9168766140937805, 'how many shares of common stock ?', '581,593,037']",shares of common stock,0.9168766140937804,how many shares of common stock ?,"581,593,037",Shares of common stock
2,"Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2020 and December 31, 2019","10,000","['Preferred stock, shares authorized', 'Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,cnc,"Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2020 and December 31, 2019","10,000",CARDINAL,"Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2020 and December 31, 2019",['Preferred stock'],"['Preferred stock', 0.8452510833740234, 'how many Preferred stock ?', '10,000']",Preferred stock,0.8452510833740234,how many Preferred stock ?,"10,000",Preferred stock authorized shares
3,"Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2020 and December 31, 2019","10,000","['Preferred stock, shares authorized', 'Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,cnc,"Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2020 and December 31, 2019","10,000",CARDINAL,"Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2020 and December 31, 2019",['Preferred stock'],"['Preferred stock', 0.8452510833740234, 'how many Preferred stock ?', '10,000']",Preferred stock,0.8452510833740234,how many Preferred stock ?,"10,000",Preferred stock shares authorized
4,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","800,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,cnc,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","800,000",CARDINAL,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019",['Common stock'],"['Common stock', 0.8710393905639648, 'how many Common stock ?', '800,000']",Common stock,0.8710393905639648,how many Common stock ?,"800,000",Authorized shares
5,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","800,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,cnc,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","800,000",CARDINAL,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019",['Common stock'],"['Common stock', 0.8710393905639648, 'how many Common stock ?', '800,000']",Common stock,0.8710393905639648,how many Common stock ?,"800,000",Authorized shares
6,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","598,249","['Common stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,cnc,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","598,249",CARDINAL,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019",['Common stock'],"['issued', 0.9468178153038025, 'What is 598,249 ?', 'issued']",issued,0.9468178153038024,"What is 598,249 ?",issued,Common stock authorized shares
7,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","581,479","['Common stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,cnc,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","581,479",CARDINAL,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019",['Common stock'],"['outstanding', 0.8782486319541931, 'What is 581,479 ?', 'outstanding']",outstanding,0.8782486319541931,"What is 581,479 ?",outstanding,"common stock outstanding at December 31, 2020"
8,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","421,508","['Common stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,cnc,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","421,508",CARDINAL,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019",['Common stock'],"['issued', 0.4299747049808502, 'What is 421,508 ?', 'issued']",issued,0.4299747049808502,"What is 421,508 ?",issued,"Common stock issued at December 31, 2019"
9,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","415,048","['Common stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,cnc,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019","415,048",CARDINAL,"Common stock, $0.001 par value; authorized 800,000 shares; 598,249 issued and 581,479 outstanding at December 31, 2020, and 421,508 issued and 415,048 outstanding at December 31, 2019",['Common stock'],"['outstanding', 0.9408758878707886, 'What is 415,048 ?', 'outstanding']",outstanding,0.9408758878707886,"What is 415,048 ?",outstanding,"Common stock outstanding at December 31, 2019"
10,"Centene Corporation, or the Company, is a leading multi national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach with local brands and local teams to provide fully integrated, high quality, and cost effective services to government sponsored and commercial healthcare programs, focusing on under insured and uninsured individuals. The Company operates in two segments: Managed Care and Specialty Services. The Managed Care segment provides health plan coverage to individuals through government subsidized programs, including Medicaid, the State Children's Health Insurance Program (CHIP), Long Term Services and Supports (LTSS), Foster Care, Medicare Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare, the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare (including Medicare Prescription Drug Plans), and the Health Insurance Marketplace. The Company also offers a variety of individual, small group, and large group commercial healthcare products, both to employers and directly to members in the Managed Care segment. The Specialty Services segment consists of the Company's specialty companies offering auxiliary healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations, as well as to the Company's own subsidiaries. The Specialty Services segment also includes the government contracts business which includes the Company's government sponsored managed care support contract with the U.S. Department of Defense (DoD) under the TRICARE program and other healthcare related government contracts.",two,['Number of reportable segments'],us-gaap_NumberOfReportableSegments,integerItemType,cnc,The Company operates in two segments: Managed Care and Specialty Services.,two,CARDINAL,The Company operates in two segments: Managed Care and Specialty Services.,[],"['', 0, '', '']",,0.0,,,The Company segments
11,"On January 23, 2020, the Company acquired all of the issued and outstanding shares of WellCare. The transaction was valued at approximately $19,555 million, including the assumption of $1,950 million of outstanding debt. The WellCare Acquisition brought a high quality Medicare platform and further extended the Company's robust Medicaid offerings. The combination enables the Company to provide access to more comprehensive and differentiated solutions across more markets with a continued focus on affordable, high quality, culturally sensitive healthcare services.","19,555",['Transaction value'],cnc_BusinessCombinationTransactionValue,monetaryItemType,cnc,"The transaction was valued at approximately $19,555 million, including the assumption of $1,950 million of outstanding debt.","approximately $19,555 million",MONEY,"The transaction was valued at approximately $19,555 million, including the assumption of $1,950 million of outstanding debt.","['assumption', 'outstanding debt']","['', 0, '', '']",,0.0,,,The transaction
12,"On January 23, 2020, the Company acquired all of the issued and outstanding shares of WellCare. The transaction was valued at approximately $19,555 million, including the assumption of $1,950 million of outstanding debt. The WellCare Acquisition brought a high quality Medicare platform and further extended the Company's robust Medicaid offerings. The combination enables the Company to provide access to more comprehensive and differentiated solutions across more markets with a continued focus on affordable, high quality, culturally sensitive healthcare services.","1,950",['Debt assumed'],us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred,monetaryItemType,cnc,"The transaction was valued at approximately $19,555 million, including the assumption of $1,950 million of outstanding debt.","$1,950 million",MONEY,"The transaction was valued at approximately $19,555 million, including the assumption of $1,950 million of outstanding debt.","['assumption', 'outstanding debt']","['outstanding debt', 0.9793716073036194, 'what is outstanding debt ?', '$1,950 million']",outstanding debt,0.9793716073036194,what is outstanding debt ?,"$1,950 million",Outstanding debt
13,"The Company receives the majority of its revenues under contracts or subcontracts with state Medicaid managed care programs. Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",11,['Percentage of revenues under contracts or subcontracts'],cnc_PercentageOfRevenuesUnderContractsOrSubcontracts,percentItemType,cnc,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",11% and 13%,PERCENT,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.","['% of total annual revenues', 'state of California', 'percentage of total revenue', 'state of New York', 'percentage of total revenue', 'state of Texas', 'percentage of total revenue', 'aggregate annual contract revenues', 'total annual revenues', 'total revenue', 'total revenue', 'total revenue']","['', 0, '', '']",,0.0,,,the state of California
14,"The Company receives the majority of its revenues under contracts or subcontracts with state Medicaid managed care programs. Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",13,['Percentage of revenues under contracts or subcontracts'],cnc_PercentageOfRevenuesUnderContractsOrSubcontracts,percentItemType,cnc,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",11% and 13%,PERCENT,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.","['% of total annual revenues', 'state of California', 'percentage of total revenue', 'state of New York', 'percentage of total revenue', 'state of Texas', 'percentage of total revenue', 'aggregate annual contract revenues', 'total annual revenues', 'total revenue', 'total revenue', 'total revenue']","['', 0, '', '']",,0.0,,,"The state of California's total revenue

Entity: 
11% and 15%
Phrase:
The state of New York's total revenue

Entity: 
10%
Phrase:
The state of Texas' total revenue"
15,"The Company receives the majority of its revenues under contracts or subcontracts with state Medicaid managed care programs. Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",11,['Percentage of revenues under contracts or subcontracts'],cnc_PercentageOfRevenuesUnderContractsOrSubcontracts,percentItemType,cnc,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",11% and 13%,PERCENT,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.","['% of total annual revenues', 'state of California', 'percentage of total revenue', 'state of New York', 'percentage of total revenue', 'state of Texas', 'percentage of total revenue', 'aggregate annual contract revenues', 'total annual revenues', 'total revenue', 'total revenue', 'total revenue']","['', 0, '', '']",,0.0,,,"the percentage of the Company's total revenue for the years ended December 31, 2019 and 2018

Entity:
11% and 15%
Phrase: 
the percentage of the Company's total revenue for the years ended December 31, 2020 and 2019

Entity:
10%
Phrase:
the percentage of the Company's total revenue for the year ended December 31, 2018"
16,"The Company receives the majority of its revenues under contracts or subcontracts with state Medicaid managed care programs. Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",15,['Percentage of revenues under contracts or subcontracts'],cnc_PercentageOfRevenuesUnderContractsOrSubcontracts,percentItemType,cnc,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",11% and 15%,PERCENT,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.","['% of total annual revenues', 'state of California', 'percentage of total revenue', 'state of New York', 'percentage of total revenue', 'state of Texas', 'percentage of total revenue', 'aggregate annual contract revenues', 'total annual revenues', 'total revenue', 'total revenue', 'total revenue']","['', 0, '', '']",,0.0,,,The state of New York
17,"The Company receives the majority of its revenues under contracts or subcontracts with state Medicaid managed care programs. Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",10,['Percentage of revenues under contracts or subcontracts'],cnc_PercentageOfRevenuesUnderContractsOrSubcontracts,percentItemType,cnc,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.",10%,PERCENT,"Customers where the aggregate annual contract revenues exceeded 10% of total annual revenues included the state of California, where the percentage of the Company's total revenue was 11% and 13% for the years ended December 31, 2019 and 2018, respectively; the state of New York, where the percentage of the Company's total revenue was 11% and 15% for the years ended December 31, 2020 and 2019, respectively, and the state of Texas, where the percentage of the Company's total revenue was 10% for the year ended December 31, 2018.","['% of total annual revenues', 'state of California', 'percentage of total revenue', 'state of New York', 'percentage of total revenue', 'state of Texas', 'percentage of total revenue', 'aggregate annual contract revenues', 'total annual revenues', 'total revenue', 'total revenue', 'total revenue']","['% of total annual revenues', 0.9133331179618835, 'what is % of total annual revenues ?', '10%']",% of total annual revenues,0.9133331179618835,what is % of total annual revenues ?,10%,Total annual revenues
18,"On January 23, 2020, the Company acquired all of the issued and outstanding shares of WellCare. The transaction was valued at $19,555 million, including the assumption of debt. The WellCare Acquisition brought a high quality Medicare platform and further extended the Company's robust Medicaid offerings. The WellCare Acquisition also enables the Company to provide access to more comprehensive and differentiated solutions across more markets with a continued focus on affordable, high quality, culturally sensitive healthcare services. With the WellCare Acquisition, the Company further broadened its product offerings by adding a Medicare prescription drug plan (PDP) to its existing business lines.","19,555",['Transaction value'],cnc_BusinessCombinationTransactionValue,monetaryItemType,cnc,"The transaction was valued at $19,555 million, including the assumption of debt.","$19,555 million",MONEY,"The transaction was valued at $19,555 million, including the assumption of debt.",['assumption of debt'],"['assumption of debt', 0.3793443441390991, 'What is $19,555 million ?', 'assumption of debt']",assumption of debt,0.3793443441390991,"What is $19,555 million ?",assumption of debt,Transaction valued
19,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.","17,605",['Total acquisition consideration'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,cnc,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","$17,605 million",MONEY,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million based on Centene's stock price of $66.76, $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","['stock price', 'fair value of equity awards', 'Total consideration', 'Centene common shares', 'stock price', 'fair value', 'equity awards', 'pre combination service']","['', 0, '', '']",,0.0,,,Total consideration paid for the acquisition
20,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.","11,431",['Equity value issued in business acquisition'],us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable,monetaryItemType,cnc,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","$11,431 million",MONEY,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million based on Centene's stock price of $66.76, $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","['stock price', 'fair value of equity awards', 'Total consideration', 'Centene common shares', 'stock price', 'fair value', 'equity awards', 'pre combination service']","['Centene common shares', 0.8813416957855225, 'what is Centene common shares ?', '$11,431 million']",Centene common shares,0.8813416957855225,what is Centene common shares ?,"$11,431 million",Centene common shares
21,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.","6,079",['Cash payments to acquire business'],us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,cnc,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","$6,079 million",MONEY,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million based on Centene's stock price of $66.76, $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","['stock price', 'fair value of equity awards', 'Total consideration', 'Centene common shares', 'stock price', 'fair value', 'equity awards', 'pre combination service']","['cash', 0.9106096625328064, 'What is $6,079 million ?', 'cash']",cash,0.9106096625328064,"What is $6,079 million ?",cash,Total consideration paid
22,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.",95,['Fair value adjustment to stock based compensation associated with pre combination service'],us-gaap_BusinessCombinationConsiderationTransferredOther1,monetaryItemType,cnc,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.",$95 million,MONEY,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million based on Centene's stock price of $66.76, $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service.","['stock price', 'fair value of equity awards', 'Total consideration', 'Centene common shares', 'stock price', 'fair value', 'equity awards', 'pre combination service']","['fair value of equity awards', 0.7092681527137756, 'what is fair value of equity awards ?', '$95 million']",fair value of equity awards,0.7092681527137756,what is fair value of equity awards ?,$95 million,fair value of replacement equity awards
23,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.",3.38,['Common stock converted into right to to Centene common stock'],cnc_BusinessCombinationCommonStockSharesReceivedPerCommonStockSharesOwned,pureItemType,cnc,"Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash.",3.38,CARDINAL,"Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash.","['shares', 'WellCare share']","['WellCare share', 0.7825819253921509, 'how many WellCare share ?', '3.38']",WellCare share,0.7825819253921509,how many WellCare share ?,3.38,Validly issued fully paid non assessable Centene common stock
24,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.",171,['Shares issued in business acquisition'],us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued,sharesItemType,cnc,"In total, 171 million shares of Centene common stock were issued to the WellCare stockholders.",171 million,CARDINAL,"In total, 171 million shares of Centene common stock were issued to the WellCare stockholders.","['shares of Centene common stock', 'Centene common stock', 'WellCare stockholders']","['WellCare stockholders', 0.9310283660888672, 'how many WellCare stockholders ?', '171 million']",WellCare stockholders,0.9310283660888672,how many WellCare stockholders ?,171 million,Centene common stock
25,"Total consideration paid for the acquisition was $17,605 million, consisting of Centene common shares valued at $11,431 million (based on Centene's stock price of $66.76), $6,079 million in cash, and $95 million related to the fair value of replacement equity awards associated with pre combination service. Each WellCare share was converted into 3.38 shares of validly issued, fully paid, non assessable Centene common stock and $120.00 in cash. In total, 171 million shares of Centene common stock were issued to the WellCare stockholders. The cash portion of the acquisition was funded through the issuance of long term debt as further discussed in Note 10. Debt. The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.",602,['Acquisition related costs'],us-gaap_BusinessCombinationAcquisitionRelatedCosts,monetaryItemType,cnc,"The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.",$602 million,MONEY,"The Company recognized $602 million of acquisition related costs, primarily related to WellCare, that are included in the Consolidated Statements of Operations for the year ended December 31, 2020.",[],"['acquisition related costs', 0.9311404824256897, 'What is $602 million ?', 'acquisition related costs']",acquisition related costs,0.9311404824256896,What is $602 million ?,acquisition related costs,Acquisition related costs
26,"(a) The identifiable intangible assets acquired are to be measured at fair value as of the completion of the acquisition. The fair value of intangible assets is determined primarily using variations of the income approach, which is based on the present value of the future after tax cash flows attributable to each identified intangible asset. Other valuation methods, including the market approach and cost approach, were also considered in estimating the fair value. The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life of 14 years. The identifiable intangible assets include purchased contract rights and customer relationships, provider contracts, trade names and developed technologies.","6,632","['Intangibles assets', 'Intangible assets']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles,monetaryItemType,cnc,"The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life of 14 years.","$6,632 million",MONEY,"The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life of 14 years.","['fair value of intangible assets', 'weighted average life of years', 'fair value', 'intangible assets', 'weighted average life']","['fair value of intangible assets', 0.9779397249221802, 'what is fair value of intangible assets ?', '$6,632 million']",fair value of intangible assets,0.9779397249221802,what is fair value of intangible assets ?,"$6,632 million",The Company has estimated the fair value of intangible assets.
27,"(a) The identifiable intangible assets acquired are to be measured at fair value as of the completion of the acquisition. The fair value of intangible assets is determined primarily using variations of the income approach, which is based on the present value of the future after tax cash flows attributable to each identified intangible asset. Other valuation methods, including the market approach and cost approach, were also considered in estimating the fair value. The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life of 14 years. The identifiable intangible assets include purchased contract rights and customer relationships, provider contracts, trade names and developed technologies.",14,"['Acquired finite lived intangible assets, weighted average useful life']",us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,cnc,"The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life of 14 years.",14 years,DATE,"The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life of 14 years.","['fair value of intangible assets', 'weighted average life of years', 'fair value', 'intangible assets', 'weighted average life']","['weighted average life', 0.964421272277832, 'what is weighted average life ?', '14 years']",weighted average life,0.964421272277832,what is weighted average life ?,14 years,"The Company has estimated the fair value of intangible assets to be $6,632 million with a weighted average life."
28,"(b) Debt is required to be measured at fair value under the acquisition method of accounting. The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million. The $105 million increase is amortized as a reduction to interest expense over the remaining life of the debt.","1,950","['Debt assumed, aggregate principal']",cnc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLongtermDebtPrincipal,monetaryItemType,cnc,"The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million.","$1,950 million",MONEY,"The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million.","['fair value of aggregate principle', 'aggregate principle of Senior Notes', 'fair value', 'aggregate principle', 'Senior Notes']","['fair value of aggregate principle', 0.7622354626655579, 'what is fair value of aggregate principle ?', '$1,950 million']",fair value of aggregate principle,0.7622354626655579,what is fair value of aggregate principle ?,"$1,950 million",Senior Notes
29,"(b) Debt is required to be measured at fair value under the acquisition method of accounting. The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million. The $105 million increase is amortized as a reduction to interest expense over the remaining life of the debt.","2,055","['Long term debt', 'Debt assumed in acquisition']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt,monetaryItemType,cnc,"The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million.","$2,055 million",MONEY,"The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million.","['fair value of aggregate principle', 'aggregate principle of Senior Notes', 'fair value', 'aggregate principle', 'Senior Notes']","['Senior Notes', 0.18158935010433197, 'what is Senior Notes ?', '$2,055 million']",Senior Notes,0.1815893501043319,what is Senior Notes ?,"$2,055 million",Senior Notes
30,"(b) Debt is required to be measured at fair value under the acquisition method of accounting. The fair value of WellCare's aggregate principle of $1,950 million Senior Notes assumed in the acquisition was $2,055 million. The $105 million increase is amortized as a reduction to interest expense over the remaining life of the debt.",105,"['Debt assumed, excess of principal']",cnc_BusinessCombinationLongtermDebtAssumedExcessOfPrincipal,monetaryItemType,cnc,The $105 million increase is amortized as a reduction to interest expense over the remaining life of the debt.,$105 million,MONEY,The $105 million increase is amortized as a reduction to interest expense over the remaining life of the debt.,"['reduction to interest expense', 'reduction over remaining life', 'remaining life of debt', 'interest expense']","['reduction to interest expense', 0.5277326703071594, 'what is reduction to interest expense ?', '$105 million']",reduction to interest expense,0.5277326703071594,what is reduction to interest expense ?,$105 million,Interest expense
31,(c) The deferred tax liabilities are presented net of $355 million of deferred tax assets.,355,['Deferred tax assets'],us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets,monetaryItemType,cnc,(c)    The deferred tax liabilities are presented net of $355 million of deferred tax assets.,$355 million,MONEY,    The deferred tax liabilities are presented net of $355 million of deferred tax assets.,"['net', 'deferred tax liabilities', 'tax assets']","['deferred tax liabilities', 0.5255861282348633, 'what is deferred tax liabilities ?', 'net of $355 million of deferred tax assets']",deferred tax liabilities,0.5255861282348633,what is deferred tax liabilities ?,net of $355 million of deferred tax assets,deferred tax assets
32,"(d) The acquisition resulted in $11,111 million of goodwill primarily related to synergies expected from the acquisition and the assembled workforce of WellCare. Substantially all of the goodwill has been assigned to the Managed Care segment. The majority of the goodwill is not deductible for income tax purposes.","11,111",['Goodwill'],us-gaap_Goodwill,monetaryItemType,cnc,"(d)    The acquisition resulted in $11,111 million of goodwill primarily related to synergies expected from the acquisition and the assembled workforce of WellCare.","$11,111 million",MONEY,"    The acquisition resulted in $11,111 million of goodwill primarily related to synergies expected from the acquisition and the assembled workforce of WellCare.",['assembled workforce of WellCare'],"['goodwill', 0.978184700012207, 'What is $11,111 million ?', 'goodwill']",goodwill,0.978184700012207,"What is $11,111 million ?",goodwill,Goodwill from the acquisition
33,"Immediately prior to the closing of the WellCare Acquisition, Anthem, Inc. acquired WellCare's Missouri Medicaid health plan, a WellCare Missouri Medicare Advantage health plan, and WellCare's Nebraska Medicaid health plan. CVS Health Corporation acquired portions of Centene's Illinois Medicaid and Medicare Advantage health plans as part of previously announced divestiture agreements. The Company recorded $104 million in pre tax gains for the year ended December 31, 2020, as a result of the Illinois divestiture, which is included in investment and other income on the Consolidated Statements of Operations.",104,['Gain on divestiture'],us-gaap_GainLossOnSaleOfBusiness,monetaryItemType,cnc,"The Company recorded $104 million in pre tax gains for the year ended December 31, 2020, as a result of the Illinois divestiture, which is included in investment and other income on the Consolidated Statements of Operations.",$104 million,MONEY,"The Company recorded $104 million in pre tax gains for the year ended December 31, 2020, as a result of the Illinois divestiture, which is included in investment and other income on the Consolidated Statements of Operations.","['result of Illinois divestiture', 'other income on Consolidated Statements', 'pre tax gains', 'Illinois divestiture']","['pre tax gains', 0.9384511709213257, 'What is $104 million ?', 'pre tax gains']",pre tax gains,0.9384511709213256,What is $104 million ?,pre tax gains,Pre tax gains
34,"From the acquisition date through December 31, 2020, the Company's Consolidated Statement of Operations include total WellCare revenues of $30,709 million. It is impracticable for the Company to determine the effect on net income resulting from the WellCare acquisition for the year ended December 31, 2020, as the Company immediately began integrating WellCare into its ongoing operations.","30,709","['Revenue of acquiree since acquisition date, actual']",us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual,monetaryItemType,cnc,"From the acquisition date through December 31, 2020, the Company's Consolidated Statement of Operations include total WellCare revenues of $30,709 million.","$30,709 million",MONEY,"From the acquisition date through December 31, 2020, the Company's Consolidated Statement of Operations include total WellCare revenues of $30,709 million.","['total WellCare revenues', 'acquisition date', 'total WellCare revenues']","['total WellCare revenues', 0.9510697722434998, 'what is total WellCare revenues ?', '$30,709 million']",total WellCare revenues,0.9510697722434998,what is total WellCare revenues ?,"$30,709 million",WellCare's total revenues
35,"The unaudited pro forma total revenues for the year ended December 31, 2020 was $112,905 million. It is impracticable for the Company to determine the pro forma earnings information for the year ended December 31, 2020 due to the nature of obtaining that information as the Company immediately began integrating WellCare into its ongoing operations.","112,905",['Total revenues'],us-gaap_BusinessAcquisitionsProFormaRevenue,monetaryItemType,cnc,"The unaudited pro forma total revenues for the year ended December 31, 2020 was $112,905 million.","$112,905 million",MONEY,"The unaudited pro forma total revenues for the year ended December 31, 2020 was $112,905 million.","['unaudited total revenues for year', 'unaudited total revenues']","['unaudited total revenues for year', 0.9403566122055054, 'what is unaudited total revenues for year ?', '$112,905 million']",unaudited total revenues for year,0.9403566122055054,what is unaudited total revenues for year ?,"$112,905 million","Total revenues for the year ended December 31, 2020"
36,"Elimination of historical WellCare intangible asset amortization expense and addition of amortization expense based on the fair value of identifiable intangible assets of approximately $6,632 million.","6,632","['Intangibles assets', 'Intangible assets']",us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles,monetaryItemType,cnc,"Elimination of historical WellCare intangible asset amortization expense and addition of amortization expense based on the fair value of identifiable intangible assets of approximately $6,632 million.","approximately $6,632 million",MONEY,"Elimination of historical WellCare intangible asset amortization expense and addition of amortization expense based on the fair value of identifiable intangible assets of approximately $6,632 million.","['Elimination of historical intangible amortization expense', 'addition of amortization expense', 'fair value of identifiable intangible assets', 'identifiable intangible assets', 'historical intangible amortization expense', 'amortization expense', 'fair value', 'identifiable intangible assets']","['identifiable intangible assets', 0.09594874083995819, 'What is approximately $6,632 million ?', 'identifiable intangible assets']",identifiable intangible assets,0.0959487408399581,"What is approximately $6,632 million ?",identifiable intangible assets,Elimination of historical WellCare intangible asset amortization expense
37,Issuance of 171 million shares of Centene common stock in connection with the per share common stock consideration.,171,['Shares issued in business acquisition'],us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued,sharesItemType,cnc,Issuance of 171 million shares of Centene common stock in connection with the per share common stock consideration.,171 million,CARDINAL,Issuance of 171 million shares of Centene common stock in connection with the per share common stock consideration.,"['Issuance of shares', 'shares of Centene common stock', 'Issuance in connection', 'connection with common stock consideration', 'share', 'Centene common stock', 'common stock consideration']","['Issuance of shares', 0.9148810505867004, 'how many Issuance of shares ?', '171 million']",Issuance of shares,0.9148810505867004,how many Issuance of shares ?,171 million,shares of Centene common stock
38,"In January 2021, the Company announced that it entered into a definitive merger agreement under which it will acquire Magellan Health for $95.00 per share in cash for a total enterprise value of approximately $2,200 million.","2,200",['Cash payments to acquire business'],us-gaap_PaymentsToAcquireBusinessesGross,monetaryItemType,cnc,"In January 2021, the Company announced that it entered into a definitive merger agreement under which it will acquire Magellan Health for $95.00 per share in cash for a total enterprise value of approximately $2,200 million.","approximately $2,200 million",MONEY,"In January 2021, the Company announced that it entered into a definitive merger agreement under which it will acquire Magellan Health for $95.00 per share in cash for a total enterprise value of approximately $2,200 million.","['total enterprise value', 'definitive merger agreement', 'total enterprise value']","['enterprise value', 0.31030401587486267, 'What is approximately $2,200 million ?', 'enterprise value']",enterprise value,0.3103040158748626,"What is approximately $2,200 million ?",enterprise value,definitive merger agreement
39,"The Company's investments are debt securities classified as available for sale with the exception of equity securities, certain private equity investments and life insurance contracts. The Company's investment policies are designed to provide liquidity, preserve capital and maximize total return on invested assets with the focus on high credit quality securities. The Company limits the size of investment in any single issuer other than U.S. treasury securities and obligations of U.S. government corporations and agencies. As of December 31, 2020, 97% of the Company's investments in rated securities carry an investment grade rating by nationally recognized statistical rating organizations. At December 31, 2020, the Company held certificates of deposit, equity securities, private equity investments and life insurance contracts, which did not carry a credit rating. Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.",97,['Percentage of investment grade investments rated by nationally recognized statistical rating organizations'],us-gaap_ConcentrationRiskPercentage1,percentItemType,cnc,"As of December 31, 2020, 97% of the Company's investments in rated securities carry an investment grade rating by nationally recognized statistical rating organizations.",97%,PERCENT,"As of December 31, 2020, 97% of the Company's investments in rated securities carry an investment grade rating by nationally recognized statistical rating organizations.","['% of investments', 'investments in rated securities', 'grade rating', 'statistical rating organizations']","['% of investments', 0.7689999938011169, 'what is % of investments ?', '97%']",% of investments,0.7689999938011169,what is % of investments ?,97%,Rated securities investment grade rating
40,"The Company's investments are debt securities classified as available for sale with the exception of equity securities, certain private equity investments and life insurance contracts. The Company's investment policies are designed to provide liquidity, preserve capital and maximize total return on invested assets with the focus on high credit quality securities. The Company limits the size of investment in any single issuer other than U.S. treasury securities and obligations of U.S. government corporations and agencies. As of December 31, 2020, 97% of the Company's investments in rated securities carry an investment grade rating by nationally recognized statistical rating organizations. At December 31, 2020, the Company held certificates of deposit, equity securities, private equity investments and life insurance contracts, which did not carry a credit rating. Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.",86,['Accrued interest income'],us-gaap_AccruedInvestmentIncomeReceivable,monetaryItemType,cnc,"Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.",$86 million,MONEY,"Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.","['Accrued interest income', 'other current assets on Consolidated Balance Sheet', 'interest income', 'sale debt securities', 'other current assets']","['Accrued interest income', 0.6445490717887878, 'what is Accrued interest income ?', '$86 million']",Accrued interest income,0.6445490717887878,what is Accrued interest income ?,$86 million,"Available for sale debt securities

Entity:
$62 million
Phrase:
Available for sale debt securities"
41,"The Company's investments are debt securities classified as available for sale with the exception of equity securities, certain private equity investments and life insurance contracts. The Company's investment policies are designed to provide liquidity, preserve capital and maximize total return on invested assets with the focus on high credit quality securities. The Company limits the size of investment in any single issuer other than U.S. treasury securities and obligations of U.S. government corporations and agencies. As of December 31, 2020, 97% of the Company's investments in rated securities carry an investment grade rating by nationally recognized statistical rating organizations. At December 31, 2020, the Company held certificates of deposit, equity securities, private equity investments and life insurance contracts, which did not carry a credit rating. Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.",62,['Accrued interest income'],us-gaap_AccruedInvestmentIncomeReceivable,monetaryItemType,cnc,"Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.",$62 million,MONEY,"Accrued interest income on available for sale debt securities was $86 million and $62 million at December 31, 2020 and 2019, respectively, and is included in other current assets on the Consolidated Balance Sheet.","['Accrued interest income', 'other current assets on Consolidated Balance Sheet', 'interest income', 'sale debt securities', 'other current assets']","['interest income on available for sale debt securities', 0.46990111470222473, 'What is $62 million ?', 'interest income on available for sale debt securities']",interest income on available for sale debt securities,0.4699011147022247,What is $62 million ?,interest income on available for sale debt securities,Available for sale debt securities
42,"The Company's residential mortgage backed securities are primarily issued by the Federal National Mortgage Association, Government National Mortgage Association or Federal Home Loan Mortgage Corporation, which carry implicit or explicit guarantees of the U.S. government. The Company's commercial mortgage backed securities are primarily senior tranches with a weighted average rating of AA+ and a weighted average duration of 4 years at December 31, 2020.",4,"['Investments that carry rating of A A plus, weighted average, duration']",cnc_InvestmentsRecordedAtFairValueThatCarryRatingOfAAPlusWeightedAverageDuration,durationItemType,cnc,"The Company's commercial mortgage backed securities are primarily senior tranches with a weighted average rating of AA+ and a weighted average duration of 4 years at December 31, 2020.",4 years,DATE,"The Company's commercial mortgage backed securities are primarily senior tranches with a weighted average rating of AA+ and a weighted average duration of 4 years at December 31, 2020.","['weighted average rating of AA+ of weighted average duration', 'weighted average duration of years', 'weighted average rating at December', 'weighted average rating', 'average duration']","['average duration', 0.8559901118278503, 'what is average duration ?', '4 years']",average duration,0.8559901118278503,what is average duration ?,4 years,Weighted average duration
43,"The Company utilizes matrix pricing services to estimate fair value for securities which are not actively traded on the measurement date. The Company designates these securities as Level II fair value measurements. In addition, the aggregate carrying amount of the Company's private equity investments and life insurance contracts, which approximates fair value, was $1,006 million and $812 million as of December 31, 2020, and December 31, 2019, respectively.","1,006",['Aggregate carrying value which approximates fair value'],cnc_LifeInsuranceContractsAndEquityInvestmentsFairValue,monetaryItemType,cnc,"In addition, the aggregate carrying amount of the Company's private equity investments and life insurance contracts, which approximates fair value, was $1,006 million and $812 million as of December 31, 2020, and December 31, 2019, respectively.","$1,006 million and $812 million",MONEY,"In addition, the aggregate carrying amount of the Company's private equity investments and life insurance contracts, which approximates fair value, was $1,006 million and $812 million as of December 31, 2020, and December 31, 2019, respectively.","['carrying amount of private equity investments', 'private equity investments', 'fair value']","['private equity investments and life insurance contracts', 0.5081661939620972, 'What is $1,006 million and $812 million ?', 'private equity investments and life insurance contracts']",private equity investments and life insurance contracts,0.5081661939620972,"What is $1,006 million and $812 million ?",private equity investments and life insurance contracts,The Company's private equity investments and life insurance contracts
44,"The Company utilizes matrix pricing services to estimate fair value for securities which are not actively traded on the measurement date. The Company designates these securities as Level II fair value measurements. In addition, the aggregate carrying amount of the Company's private equity investments and life insurance contracts, which approximates fair value, was $1,006 million and $812 million as of December 31, 2020, and December 31, 2019, respectively.",812,['Aggregate carrying value which approximates fair value'],cnc_LifeInsuranceContractsAndEquityInvestmentsFairValue,monetaryItemType,cnc,"In addition, the aggregate carrying amount of the Company's private equity investments and life insurance contracts, which approximates fair value, was $1,006 million and $812 million as of December 31, 2020, and December 31, 2019, respectively.","$1,006 million and $812 million",MONEY,"In addition, the aggregate carrying amount of the Company's private equity investments and life insurance contracts, which approximates fair value, was $1,006 million and $812 million as of December 31, 2020, and December 31, 2019, respectively.","['carrying amount of private equity investments', 'private equity investments', 'fair value']","['private equity investments and life insurance contracts', 0.5081661939620972, 'What is $1,006 million and $812 million ?', 'private equity investments and life insurance contracts']",private equity investments and life insurance contracts,0.5081661939620972,"What is $1,006 million and $812 million ?",private equity investments and life insurance contracts,Company's private equity investments and life insurance contracts
45,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.",487,['Depreciation expense'],us-gaap_Depreciation,monetaryItemType,cnc,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.",$487 million,MONEY,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.","['Depreciation expense for years', 'Depreciation expense']","['Depreciation expense', 0.8676829934120178, 'What is $487 million ?', 'Depreciation expense']",Depreciation expense,0.8676829934120178,What is $487 million ?,Depreciation expense,"Depreciation expense for the year ended December 31, 2020"
46,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.",342,['Depreciation expense'],us-gaap_Depreciation,monetaryItemType,cnc,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.",$342 million,MONEY,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.","['Depreciation expense for years', 'Depreciation expense']","['', 0, '', '']",,0.0,,,"Depreciation expense for the year ended December 31, 2019"
47,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.",237,['Depreciation expense'],us-gaap_Depreciation,monetaryItemType,cnc,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.",$237 million,MONEY,"Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $487 million, $342 million and $237 million, respectively.","['Depreciation expense for years', 'Depreciation expense']","['', 0, '', '']",,0.0,,,"Depreciation expense for the year ended December 31, 2018"
48,"The majority of the increase in the managed care segment goodwill in 2020 was related to the acquisition and fair value allocations related to the WellCare acquisition discussed in Note 3. Acquisitions. The majority of the increase in the specialty services segment goodwill related to the acquisitions of Apixio and PANTHERx. As part of the sale of certain products of the Illinois health plan due to the WellCare acquisition, the Company allocated goodwill of $68 million to the Illinois health plan as part of the divestiture. The Company reallocated goodwill of $197 million from the Specialty Services segment to the Managed Care segment related to its pharmacy benefit management business based on the completion of the shift to transparent pricing. During the first quarter of 2020, the Company recorded $9 million of non cash goodwill impairment related to its third party care management software business in the Specialty Services segment.",68,"['Goodwill, allocated as part of the divestiture']",us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit,monetaryItemType,cnc,"As part of the sale of certain products of the Illinois health plan due to the WellCare acquisition, the Company allocated goodwill of $68 million to the Illinois health plan as part of the divestiture.",$68 million,MONEY,"As part of the sale of certain products of the Illinois health plan due to the WellCare acquisition, the Company allocated goodwill of $68 million to the Illinois health plan as part of the divestiture.","['part of sale', 'sale of certain products', 'certain products of Illinois health plan', 'part due WellCare acquisition', 'goodwill', 'part of divestiture', 'certain products', 'Illinois health plan', 'WellCare acquisition', 'Illinois health plan']","['goodwill', 0.9644050002098083, 'What is $68 million ?', 'goodwill']",goodwill,0.9644050002098083,What is $68 million ?,goodwill,Illinois health plan
49,"The majority of the increase in the managed care segment goodwill in 2020 was related to the acquisition and fair value allocations related to the WellCare acquisition discussed in Note 3. Acquisitions. The majority of the increase in the specialty services segment goodwill related to the acquisitions of Apixio and PANTHERx. As part of the sale of certain products of the Illinois health plan due to the WellCare acquisition, the Company allocated goodwill of $68 million to the Illinois health plan as part of the divestiture. The Company reallocated goodwill of $197 million from the Specialty Services segment to the Managed Care segment related to its pharmacy benefit management business based on the completion of the shift to transparent pricing. During the first quarter of 2020, the Company recorded $9 million of non cash goodwill impairment related to its third party care management software business in the Specialty Services segment.",197,"['Reallocation', 'Goodwill, reallocated']",us-gaap_GoodwillTransfers,monetaryItemType,cnc,The Company reallocated goodwill of $197 million from the Specialty Services segment to the Managed Care segment related to its pharmacy benefit management business based on the completion of the shift to transparent pricing.,$197 million,MONEY,The Company reallocated goodwill of $197 million from the Specialty Services segment to the Managed Care segment related to its pharmacy benefit management business based on the completion of the shift to transparent pricing.,"['goodwill', 'completion of shift', 'shift to transparent pricing', 'Services segment', 'Care segment', 'management business', 'transparent pricing']","['goodwill', 0.15052460134029388, 'What is $197 million ?', 'goodwill']",goodwill,0.1505246013402938,What is $197 million ?,goodwill,Goodwill reallocation
